Toxicology – Carbamazepine

Core concept

Carbamazepine is a sodium-channel–blocking antiseizure medication with anticholinergic properties that can cause prolonged and delayed toxicity after overdose.

The characteristic syndrome is:

Nystagmus + ataxia + CNS depression → coma/seizures ± QRS widening, hypotension, and dysrhythmias

A particularly important feature is:

Delayed or recurrent toxicity despite initial improvement

because carbamazepine can:

• Slow gastrointestinal motility
• Form pharmacobezoars/tablet concretions
• Undergo prolonged absorption
• Undergo enterohepatic/enteroenteric recirculation

Peak concentrations after large overdose may be delayed for up to 72 hours.

Forms and Uses

Carbamazepine is available as:

• Immediate-release tablets
• Chewable tablets
• Oral suspension
• Extended-release tablets/capsules

Common indications include:

• Focal epilepsy
• Generalized tonic-clonic seizures in selected patients
• Trigeminal neuralgia
• Bipolar disorder

Common brands have included:

• Tegretol
• Carbatrol
• Equetro
• Epitol

Extended-release preparations are particularly important in overdose because toxicity can be delayed and prolonged.

Toxic Dose

There is no completely reliable dose threshold.

Large adult ingestions of several grams can cause serious poisoning, while smaller amounts can produce significant effects in children.

Clinical severity depends on:

• Dose
• Formulation
• Chronic carbamazepine use
• Age
• Coingestants
• Hepatic metabolism
• Drug interactions

Therefore:

Serum concentration + clinical condition + ECG are more useful than dose alone.

Pathophysiology

Sodium-Channel Blockade

Carbamazepine stabilizes voltage-gated sodium channels in the inactive state.

At therapeutic concentrations this limits repetitive neuronal firing.

In overdose:

Excess sodium-channel blockade → neuronal dysfunction + myocardial conduction slowing

resulting in:

• Ataxia
• Nystagmus
• CNS depression
• Paradoxical seizures
• QRS widening
• Myocardial depression

Antimuscarinic Effects

Carbamazepine also has clinically relevant anticholinergic effects.

These may cause:

• Tachycardia
• Dilated pupils
• Dry mucosa
• Reduced bowel motility
• Ileus
• Urinary retention
• Delirium

Reduced intestinal motility contributes to delayed absorption and recurrent toxicity.

Active Metabolite

Carbamazepine is metabolized mainly by CYP3A4 to:

Carbamazepine-10,11-epoxide

which is pharmacologically active and can contribute to toxicity.

Valproate can inhibit metabolism of the epoxide metabolite and increase its concentration.

Drug Interactions

Drugs that can increase carbamazepine concentrations include CYP3A4 inhibitors such as:

• Clarithromycin
• Erythromycin
• Azole antifungals
• Verapamil
• Diltiazem
• Some SSRIs
• Protease inhibitors
• Grapefruit juice

Carbamazepine itself is also a potent inducer of several CYP enzymes and may reduce concentrations of many other drugs.

Clinical Features

Neurologic

Neurologic toxicity is usually the dominant presentation.

Common findings:

• Nystagmus
• Diplopia
• Dizziness
• Dysarthria
• Ataxia
• Somnolence
• Confusion

Moderate/severe poisoning can cause:

• Agitation
• Hallucinations
• Abnormal movements
• Chorea
• Myoclonus
• Seizures
• Coma

The patient’s mental status may fluctuate:

Somnolence/coma → apparent improvement → recurrent deterioration

This “cyclical coma” reflects delayed and variable drug absorption.

Cardiovascular

Possible findings include:

• Sinus tachycardia
• Hypotension
• Myocardial depression
• PR prolongation
• QRS widening
• AV block
• Ventricular dysrhythmias

The older emphasis on QT prolongation as the main ECG abnormality is less useful than recognizing:

Sodium-channel blockade → QRS widening

which is the more important toxicologic conduction abnormality.

Respiratory

Severe CNS depression may cause:

• Hypoventilation
• Loss of airway reflexes
• Aspiration
• Respiratory failure
• Apnea

Intubation may be necessary in severe poisoning.

Gastrointestinal

Possible manifestations include:

• Nausea
• Vomiting
• Reduced bowel sounds
• Ileus

Anticholinergic ileus can prolong absorption significantly.

Electrolytes

Hyponatremia

Carbamazepine can cause:

SIADH → water retention → hyponatremia

This is more typical of therapeutic/chronic use than isolated acute overdose, but it should be considered when altered mental status or seizures are disproportionate to the measured carbamazepine concentration.

Current labeling identifies SIADH-related hyponatremia as a recognized adverse effect, with greater risk in older patients and patients taking diuretics.

Musculoskeletal

Seizures, agitation, or prolonged coma may cause:

• CK elevation
• Rhabdomyolysis

Monitor CK and renal function when clinically indicated.

Serum Carbamazepine Concentrations

A major correction to the older source:

The usual therapeutic range is approximately 4–12 μg/mL = 4–12 mg/L

—not 6–12 μg/dL.

Approximate toxicity relationships:

• 11–15 mg/L: nystagmus, ataxia, disorientation
• 15–25 mg/L: agitation, hallucinations, marked CNS toxicity
• >25 mg/L: severe toxicity including seizures/coma increasingly likely
• >40 mg/L: strongly associated with severe poisoning

Individual variation is substantial.

Important

A single level is not enough after a major overdose.

Serial Carbamazepine Levels

Obtain serial concentrations approximately:

Every 4–6 hours

until:

• A clear downward trend is established
• The patient is improving clinically

This is critical because concentrations can continue rising after presentation.

A patient whose level is initially modest may deteriorate many hours later.

Why Levels Can Rise Late

Mechanisms include:

• Delayed gastric emptying
• Anticholinergic ileus
• Extended-release formulation
• Tablet concretions/pharmacobezoars
• Continued intestinal absorption
• Enterohepatic/enteroenteric recycling

Therefore:

Never discharge a clinically concerning patient solely because the first carbamazepine level is low.

Diagnosis

Diagnosis is based on:

Exposure history + neurologic syndrome + ECG + serial carbamazepine concentrations

The classic combination is:

Nystagmus + ataxia + CNS depression + tachycardia

with more severe poisoning causing:

• Seizures
• Coma
• QRS widening
• Hypotension

Essential Investigations

Obtain:

• 12-lead ECG
• Continuous cardiac monitoring
• Serial serum carbamazepine concentrations
• Glucose
• Sodium
• Potassium
• Magnesium
• Bicarbonate
• BUN
• Creatinine

Depending on severity:

• CK
• Blood gas
• Lactate
• Liver tests

For intentional overdose also consider:

• Acetaminophen concentration
• Salicylate concentration
• Other relevant coingestants

Differential Diagnosis

Toxicologic causes of CNS depression/ataxia include:

• Phenytoin
• Valproate
• Phenobarbital
• Benzodiazepines
• Alcohols
• Tricyclic antidepressants
• Other sodium-channel blockers

Non-toxicologic causes include:

• Stroke
• Intracranial hemorrhage
• CNS infection
• Hyponatremia
• Hypoglycemia
• Postictal state

Treatment

1. Airway and Ventilation

Supportive care is the foundation.

Intubate if there is:

• Significant coma
• Loss of airway protection
• Recurrent seizures
• Respiratory failure

Severe CNS depression is a recognized indication for airway control in carbamazepine toxicity.

2. IV Fluids and Hypotension

For hypotension:

• Give isotonic crystalloid if clinically volume responsive
• Avoid unnecessary fluid overload if myocardial dysfunction is suspected

Persistent shock should be treated with a direct-acting vasopressor, with:

Norepinephrine

a reasonable contemporary first choice.

The historical preference for dopamine is outdated.

3. Sodium Bicarbonate

Carbamazepine can behave like other sodium-channel blockers in severe overdose.

Indications include:

• QRS widening
• Ventricular dysrhythmia attributable to sodium-channel blockade
• Hypotension with evidence of conduction toxicity

A commonly used regimen is:

Sodium bicarbonate 1–2 mEq/kg IV bolus

repeated according to:

• QRS response
• Hemodynamics
• Acid–base status

A practical target is a serum pH approximately:

7.45–7.55

while avoiding severe alkalemia.

A QRS around >100–110 ms, especially with hemodynamic instability, is commonly used as a treatment trigger.

Monitor for:

• Hypernatremia
• Hypokalemia
• Volume overload
• Metabolic alkalosis

Ventricular Dysrhythmias

First priorities:

• Sodium bicarbonate
• Correction of oxygenation
• Correction of electrolytes

The older recommendation to move routinely to lidocaine after bicarbonate failure is based on limited evidence.

For refractory ventricular dysrhythmia:

• Follow appropriate resuscitation principles
• Seek medical-toxicology input
• Consider extracorporeal treatment early in life-threatening toxicity

4. Seizures

First-line:

Benzodiazepines

Examples:

• Lorazepam
• Midazolam
• Diazepam

If seizures persist:

• Phenobarbital may be considered
• Propofol is reasonable in an intubated patient with refractory status epilepticus

Avoid Phenytoin

The older source recommends phenytoin as a second anticonvulsant.

Modern guidance generally advises against sodium-channel–blocking antiseizure drugs such as:

Phenytoin/fosphenytoin

because carbamazepine already causes sodium-channel blockade and cardiac conduction slowing.

Thus:

Toxicologic seizures → benzodiazepines first; avoid adding another sodium-channel blocker when possible.

Gastrointestinal Decontamination

Do Not Induce Vomiting

Do not use:

• Ipecac
• Deliberate emesis

because CNS depression and seizures may develop.

Single-Dose Activated Charcoal

Activated charcoal may be appropriate after a significant recent ingestion if:

• The airway is intact or protected
• Aspiration risk is acceptable

A typical dose is approximately:

1 g/kg

with common adult dosing around 50 g.

Because absorption can be delayed, charcoal may remain useful beyond the very early period in selected cases, especially after large or extended-release ingestions.

Multiple-Dose Activated Charcoal

This is an important carbamazepine-specific therapy.

Multiple-dose activated charcoal (MDAC) increases carbamazepine elimination.

Mechanisms include:

• Interrupting enterohepatic/enteroenteric recirculation
• “Gut dialysis” of circulating drug

Toxicology guidelines specifically identify carbamazepine as one of the small number of drugs for which MDAC should be considered after a life-threatening ingestion.

Important caveat

Clinical outcome benefit is less firmly established than the pharmacokinetic benefit.

Do not give MDAC when:

• Airway is unprotected
• Significant vomiting prevents safe administration
• Ileus is present
• Intestinal obstruction is suspected

This is particularly relevant because carbamazepine itself can cause anticholinergic ileus.

Gastric Lavage

The older recommendation for routine gastric lavage after large ingestion does not reflect routine contemporary poisoning practice.

It should only rarely be considered in an exceptional:

• Massive
• Very recent
• Life-threatening ingestion

with:

• Protected airway
• Appropriate monitoring
• Toxicology consultation

Whole-Bowel Irrigation

Whole-bowel irrigation is not routine.

It may occasionally be considered after a very large extended-release ingestion when:

• Significant drug is thought to remain in the GI tract
• The patient is stable enough
• The airway is protected
• There is no ileus or obstruction

Current references caution that routine use is not established and intestinal complications are possible.

Antidote

There is no specific antidote for carbamazepine poisoning.

Treatment relies on:

• Supportive care
• Activated charcoal when appropriate
• Sodium bicarbonate for conduction toxicity
• Extracorporeal removal in severe cases

Extracorporeal Treatment

This is one of the biggest changes from the older text.

Historically:

Charcoal hemoperfusion was preferred.

Current EXTRIP guidance states:

Intermittent hemodialysis is the preferred extracorporeal treatment for severe carbamazepine poisoning.

Although carbamazepine is normally significantly protein bound, in overdose:

• Binding becomes relatively saturated
• The free fraction increases

and modern high-flux dialysis can provide clinically useful clearance.

EXTRIP Indications

Extracorporeal treatment is recommended when there are:

Refractory multiple seizures

or

Life-threatening dysrhythmias

It is also suggested when there is:

• Prolonged coma or respiratory depression requiring mechanical ventilation
• Persistent severe toxicity despite supportive care and MDAC
• Carbamazepine concentrations that remain high or continue rising despite treatment

Preferred Modality

EXTRIP recommends:

1. Intermittent hemodialysis — preferred

If unavailable:

• Intermittent hemoperfusion
• Continuous renal replacement therapy

may be used.

Therefore:

Hemoperfusion is no longer the preferred extracorporeal modality.

When to Stop Dialysis

EXTRIP recommends stopping when:

• Clinical improvement is apparent

and suggests a concentration target:

Carbamazepine <10 mg/L

MDAC should generally be continued during extracorporeal treatment when safe and feasible.

Rebound After Dialysis

Because carbamazepine can:

• Redistribute from tissue
• Continue to be absorbed from the GI tract

serum concentrations may rebound after extracorporeal therapy.

Therefore:

Continue serial carbamazepine levels after dialysis.

Clinical improvement plus a falling concentration trend is more important than one post-dialysis level.

Intravenous Lipid Emulsion

Carbamazepine is lipophilic, and IV lipid emulsion has been reported in severe poisoning.

However:

Evidence is limited largely to case reports.

It is not first-line therapy and should not delay:

• Sodium bicarbonate
• MDAC
• Hemodialysis
• Standard resuscitation

Current reviews describe lipid therapy only as a possible rescue adjunct in refractory cases.

Physostigmine

Although anticholinergic manifestations can occur:

Physostigmine should not be used routinely.

The patient may already have:

• Seizure risk
• Cardiac conduction abnormalities

and reversal of peripheral anticholinergic symptoms is not worth these risks.

Monitoring

Patients with significant toxicity require:

• Continuous ECG
• Continuous respiratory monitoring
• Frequent neurologic examination
• Serial carbamazepine concentrations
• Serial electrolytes

Monitor specifically for:

• Rising drug level
• QRS widening
• Hypotension
• Seizures
• Recurrent coma

Observation

A fixed 6-hour observation period is not reliable for all carbamazepine overdoses.

Immediate-release toxicity may begin within several hours, while sustained-release poisoning may be delayed.

A pediatric toxicology guideline notes:

• Immediate-release symptoms often appear within 1–2 hours
• Sustained-release toxicity may appear around 4–8 hours
• Mild symptomatic patients should generally be observed at least 8 hours, with longer observation for controlled-release exposures

Massive overdoses can peak much later, including up to 72 hours.

Therefore:

Large, extended-release, symptomatic, or rising-level ingestions require prolonged observation.

Admission

Admit patients with:

• Altered mental status
• Ataxia preventing safe ambulation
• Seizures
• Coma
• QRS widening
• Dysrhythmia
• Hypotension
• Rising carbamazepine concentration
• Significant extended-release overdose

Patients with:

• Severe CNS depression
• Mechanical ventilation
• Significant conduction toxicity
• Refractory seizures
• Shock
• Need for extracorporeal treatment

require ICU care.

Discharge

Discharge should require:

• Normal or baseline mental status
• Safe ambulation
• Normal/stable ECG
• No evolving cardiovascular toxicity
• No recurrent symptoms
• Clearly declining carbamazepine concentrations when levels were elevated or ingestion was significant

Do not discharge solely because the patient briefly “wakes up.”

Pregnancy

The historical FDA Pregnancy Category C system is obsolete.

Current labeling recognizes that carbamazepine can cause fetal harm and has been associated with congenital abnormalities, particularly neural tube defects such as spina bifida.

In an acute maternal overdose:

Maternal stabilization remains the priority.

Do not withhold:

• Airway support
• Sodium bicarbonate
• Seizure treatment
• Hemodialysis when indicated

because maternal hypoxia and shock represent immediate fetal threats.

Prognosis

Most mild/moderate overdoses recover with supportive treatment.

However, severe poisoning may persist for:

• 24–48 hours
• Several days after massive or extended-release ingestion

because of delayed absorption.

Serious morbidity may result from:

• Aspiration
• Prolonged hypoxia
• Refractory seizures
• Severe dysrhythmia
• Shock

Early recognition of delayed toxicity and appropriate use of MDAC and hemodialysis have substantially changed modern management.

Important Pitfalls

1. Using the wrong serum units

Therapeutic carbamazepine:

4–12 μg/mL = 4–12 mg/L

The older value expressed as μg/dL is incorrect.

2. Relying on a single drug level

The concentration may continue to rise for many hours.

Repeat every 4–6 hours until clearly falling.

3. Discharging after transient improvement

Carbamazepine can cause:

Cyclical coma

from delayed absorption and redistribution.

4. Missing sodium-channel blockade

Serious ECG toxicity is best recognized by:

QRS widening

rather than focusing only on QT prolongation.

Treat significant QRS widening with:

IV sodium bicarbonate.

5. Treating seizures with phenytoin

Phenytoin is another sodium-channel blocker and can worsen conduction toxicity.

Prefer:

• Benzodiazepines
• Phenobarbital/propofol when necessary

6. Forgetting multiple-dose activated charcoal

Carbamazepine is one of the classic drugs for which MDAC can meaningfully increase elimination after life-threatening poisoning.

7. Giving charcoal to an unprotected airway

CNS depression and vomiting create substantial aspiration risk.

Secure the airway first when necessary.

8. Using charcoal despite ileus

Carbamazepine itself may significantly decrease intestinal motility.

MDAC is contraindicated when bowel obstruction or significant ileus is present.

9. Thinking hemoperfusion is still preferred

Current EXTRIP guidance:

Intermittent hemodialysis is preferred over hemoperfusion.

10. Waiting for a particular serum concentration before dialysis

EXTRIP indications are primarily clinical:

• Refractory seizures
• Life-threatening dysrhythmia
• Prolonged ventilated coma
• Persistent severe toxicity

not simply a numerical drug concentration.

High-Yield Toxicology Pearls

Carbamazepine overdose = sodium-channel blockade + anticholinergic toxicity

Think:

Nystagmus + ataxia + CNS depression + tachycardia

Severe poisoning:

Coma/seizures + QRS widening + hypotension ± ventricular dysrhythmia

Key points:

• Mechanism: voltage-gated sodium-channel blockade
• Active metabolite: carbamazepine-10,11-epoxide
• Therapeutic serum level: 4–12 mg/L
• >40 mg/L strongly suggests severe toxicity
• Serial levels are essential
• Check approximately every 4–6 h until clearly declining
• Peak levels can be delayed up to 72 h after massive overdose
• Anticholinergic ileus and tablet concretions cause delayed absorption
• “Cyclical coma” is classic
• Important ECG finding: QRS widening
• QRS widening/hypotension → sodium bicarbonate 1–2 mEq/kg IV
• Seizures → benzodiazepines
• Avoid routine phenytoin/fosphenytoin
• No specific antidote
• Single-dose charcoal may be used after selected recent ingestions
• Multiple-dose activated charcoal is particularly important in life-threatening poisoning
• Do not use MDAC with an unprotected airway or ileus
• Modern extracorporeal therapy:
• Intermittent hemodialysis preferred
• Hemoperfusion is an alternative
• Dialysis indications include:
• Refractory seizures
• Life-threatening dysrhythmias
• Prolonged ventilated coma
• Persistent/rising toxicity despite MDAC/support
• EXTRIP suggests stopping ECTR with clinical improvement and carbamazepine <10 mg/L
• Do not discharge until clinical recovery is sustained and significant serum levels are demonstrably falling